Caris Life Sciences (CAI) had its price target lowered by Canaccord Genuity Group Inc. from $30.00 to $22.00. They now have a "hold" rating on the stock.
LowReport
Caris Life Sciences (CAI) had its price target lowered by Canaccord Genuity Group Inc. from $30.00 to $22.00. They now have a "hold" rating on the stock.
Caris Life Sciences Launches a Novel Caris AI Insights Signature to Guide First-Line Therapy Selection and Treatment De-Escalation in Pancreatic Cancer [Yahoo! Finance]
MediumReport
Caris Life Sciences Launches a Novel Caris AI Insights Signature to Guide First-Line Therapy Selection and Treatment De-Escalation in Pancreatic Cancer [Yahoo! Finance]
Caris Life Sciences Launches a Novel Caris AI Insights Signature to Guide First-Line Therapy Selection and Treatment De-Escalation in Pancreatic Cancer
MediumReport
Caris Life Sciences Launches a Novel Caris AI Insights Signature to Guide First-Line Therapy Selection and Treatment De-Escalation in Pancreatic Cancer
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Don’t Miss Out On The Next BIG Stock Move
"Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ blog email newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our blog below: